| The role of DNA mismatch repair in platinum drug resistance D Fink, S Nebel, S Aebi, H Zheng, B Cenni, A Nehmé, RD Christen, ... Cancer research 56 (21), 4881-4886, 1996 | 850 | 1996 |
| The role of DNA mismatch repair in drug resistance. D Fink, S Aebi, SB Howell Clinical cancer research: an official journal of the American Association …, 1998 | 772 | 1998 |
| Loss of DNA mismatch repair in acquired resistance to cisplatin S Aebi, B Kurdi-Haidar, R Gordon, B Cenni, H Zheng, D Fink, RD Christen, ... Cancer Research 56 (13), 3087-3090, 1996 | 715 | 1996 |
| Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 HJ Burstein, G Curigliano, B Thürlimann, WP Weber, P Poortmans, ... Annals of Oncology 32 (10), 1216-1235, 2021 | 684* | 2021 |
| Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up S Aebi, T Davidson, G Gruber, F Cardoso, ... Annals of oncology 22 (suppl 6), vi12-vi24, 2011 | 403 | 2011 |
| Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program F Cardoso, JMS Bartlett, L Slaets, CHM van Deurzen, ... Annals of Oncology 29 (2), 405-417, 2018 | 389 | 2018 |
| Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? S Aebi, S Gelber, M Castiglione-Gertsch, RD Gelber, J Collins, ... The Lancet 355 (9218), 1869-1874, 2000 | 389 | 2000 |
| In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair D Fink, H Zheng, S Nebel, PS Norris, S Aebi, TP Lin, A Nehmé, ... Cancer research 57 (10), 1841-1845, 1997 | 374 | 1997 |
| Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93 International Breast Cancer Study Group Journal of Clinical Oncology 24 (9), 1332-1341, 2006 | 314 | 2006 |
| Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. S Aebi, D Fink, R Gordon, HK Kim, H Zheng, JL Fink, SB Howell Clinical cancer research: an official journal of the American Association …, 1997 | 268 | 1997 |
| Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial S Aebi, S Gelber, SJ Anderson, I Láng, A Robidoux, M Martín, ... The Lancet Oncology 15 (2), 156-163, 2014 | 232 | 2014 |
| First international consensus guidelines for breast cancer in young women (BCY1) AH Partridge, O Pagani, O Abulkhair, S Aebi, F Amant, HA Azim Jr, ... The Breast 23 (3), 209-220, 2014 | 208 | 2014 |
| The Notch pathway in ovarian carcinomas and adenomas O Hopfer, D Zwahlen, MF Fey, S Aebi British journal of cancer 93 (6), 709-718, 2005 | 207 | 2005 |
| Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up S Aebi, T Davidson, G Gruber, M Castiglione, ... Annals of oncology 21 (suppl 5), v9-v14, 2010 | 183 | 2010 |
| Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and-deficient cells exposed to cisplatin A Nehmé, R Baskaran, S Aebi, D Fink, S Nebel, B Cenni, JYJ Wang, ... Cancer research 57 (15), 3253-3257, 1997 | 174 | 1997 |
| A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib O Gautschi, C Pauli, K Strobel, A Hirschmann, G Printzen, S Aebi, ... Journal of Thoracic Oncology 7 (10), e23-e24, 2012 | 173 | 2012 |
| Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment U Amstutz, S Farese, S Aebi, CR Largiadèr Pharmacogenomics 10 (6), 931-944, 2009 | 165 | 2009 |
| Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicity TK Froehlich, U Amstutz, S Aebi, M Joerger, CR Largiadèr International journal of cancer 136 (3), 730-739, 2015 | 160 | 2015 |
| CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials A Keshaviah, S Dellapasqua, N Rotmensz, J Lindtner, D Crivellari, ... Annals of oncology 18 (4), 701-708, 2007 | 148 | 2007 |
| Assessment of differences in patient populations selected for or excluded from participation in clinical phase III acute myelogenous leukemia trials C Mengis, S Aebi, A Tobler, W Dähler, MF Fey Journal of clinical oncology 21 (21), 3933-3939, 2003 | 134 | 2003 |
Richard GelberProfessor, Harvard Medical School, Harvard TH Chan School of Public Health, Dana-Farber Cancer Institute, Frontier Science Foundation在 ds.dfci.harvard.edu 的电子邮件经过验证